VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 2, 2005, Pages 745-752

  Rangon, Claire Marie ^a   Goursaud, Stéphanie ^b   Medja, Fadia ^a   Lelièvre, Vincent ^a   Mounien, Lourdes ^c   Husson, Isabelle ^a   Brabet, Philippe ^d   Jégou, Sylvie ^c   Janet, Thierry ^b   Gressens, Pierre ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE ROUEN   (France)

^d HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; MESSENGER RNA; NEUROENDOCRINE RECEPTOR VAPC2; NEUROPEPTIDE RECEPTOR; PEPTIDE HISTIDINE ISOLEUCINE; PROTEIN KINASE C; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; ADCYAP1 PROTEIN, MOUSE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CELL SURFACE RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; IBOTENIC ACID; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUROPROTECTIVE AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; VIPR2 PROTEIN, MOUSE;

ANIMAL MODEL; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; EXCITOTOXICITY; FEMALE; IN SITU HYBRIDIZATION; INHIBITION KINETICS; MALE; MOUSE; NEUROPROTECTION; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA ANALYSIS; WHITE MATTER; ANIMAL; BIOSYNTHESIS; BRAIN LEVEL; DRUG EFFECT; FOREBRAIN; GENETICS; IN VITRO STUDY; MEMBRANE; METABOLISM; PHYSIOLOGY; PREGNANCY;

ANIMALS; ANIMALS, NEWBORN; BRAIN CHEMISTRY; FEMALE; IBOTENIC ACID; IN SITU HYBRIDIZATION; MALE; MEMBRANES; MICE; NERVE GROWTH FACTORS; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; PEPTIDE PHI; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PREGNANCY; PROSENCEPHALON; RECEPTORS, CELL SURFACE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RNA, MESSENGER; VASOACTIVE INTESTINAL PEPTIDE;

EID: 22944464113     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.105.086405     Document Type: Article

References (38)

1. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, et al. (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72:1283-1293.
2. Bellemère G, Vaudry H, Mounien L, Boutelet I, and Jégou S (2004) Localization of the mRNA encoding prolyl endopeptidase in the rat brain and pituitary. J Comp Neurol 471:128-143.
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
4. Brenneman DE, Neale EA, Foster GA, d'Autremont SW, and Westbrook GL (1987) Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J Cell Biol 104:1603-1610.
5. Brown J and Czarnecki A (1990) Distribution of atrial natriuretic peptide receptor subtypes in rat brain. Am J Physiol 258:R1078-R1083.
6. Ciranna L and Cavallaro S (2003) Opposing effects by pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide on hippocampal synaptic transmission. Exp Neurol 184:778-784.
7. Ekblad E, Jongsma H, Brabet P, Bockaert J, and Sundler F (2000) Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse. Ann NY Acad Sci 921:137-147.
8. Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM, Morrison CF, and Harmar AJ (2001) Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide. Proc Natl Acad Sci USA 98:13854-13859.
9. Gourlet P, Vandermeers A, Vertongen P, Rathe J, De Neef P, Cnudde J, Waelbroeck M, and Robberecht P (1997a) Development of high affinity selective VIP1 receptor agonists. Peptides 10:1539-1545.
10. Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Waelbroeck M, and Robberecht P (1997b) The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides 18:403-408.
11. Gozes I, McCune SK, Jacobson L, Warren D, Moody TW, Fridkin M, and Brenneman DE (1991) An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther 257:959-966.
12. Gressens P (1999) VIP neuroprotection against excitotoxic lesions of the developing mouse brain. Ann NY Acad Sci 897:109-124.
13. Gressens P, Hill JM, Gozes I, Fridkin M, and Brenneman DE (1993) Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature (Lond) 362:155-158.
14. Gressens P, Hill JM, Paindaveine B, Gozes I, Fridkin M, and Brenneman DE (1994) Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J Clin Investig 94:2020-2027.
15. Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M, and Evrard P (1997) Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Investig 100:390-397.
16. Gressens P, Marret S, Martin JL, Laquerriere A, Lombet A, and Evrard P (1998) Regulation of neuroprotective action of vasoactive intestinal peptide in the murine developing brain by protein kinase C and mitogen-activated protein kinase cascades: in vivo and in vitro studies. J Neurochem 70:2574-2584.
17. Grinninger C, Wang W, Oskoui KB, Voice JK, and Goetzl EJ (2004) A natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function. J Biol Chem 279:40259-40262.
18. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265-270.
19. Harmar AJ, Marston H, Shen S, Spratt C, West K, Sheward W, Morrison C, Dorin J, Piggins H, and Reubi J (2002) The VPAC2 receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 109:497-508.
20. Husson I, Mesples B, Bac P, Vamecq J, Evrard P, and Gressens P (2002) Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann Neurol 51:82-92.
21. Ishihara T, Shigemoto R, Mori K, Takahashi K, and Nagata S (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8:811-819.
22. Jamen F, Persson K, Bertrand G, Rodriguez-Henche N, Puech R, Bockaert J, Ahren B, and Brabet P (2000) PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Investig 105:1307-1315.
23. Laburthe M, Couvineau A, and Marie JC (2002) VPAC receptors for VIP and PACAP. Receptors Channels 8:137-153.
24. Langer I, Perret J, Vertongen P, Waelbroeck M, and Robberecht P (2001) Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMP in CHO cells expressing Galpha16. Cell Calcium 30:229-234.
25. Langer I and Robberecht P (2005) Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation. Cell Signal 17:17-24.
26. Lutz EMSW, West KM, Morrow JA, Fink G, and Harmar AJ (1993) The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 1:3-8.
27. Marret S, Mukendi R, Gadisseux JF, Gressens P, and Evrard P (1995) Effect of ibotenate on brain development: an excitotoxic mouse model of microgyria and posthypoxic-like lesions. J Neuropathol Exp Neurol 54:358-370.
28. 125I]iodo-Tyr10,MetO17]-vasoactive intestinal polypeptide. Preparation, characterization and use for radioimmunoassay and receptor binding. J Biol Chem 261:5320-5327.
29. Milligan G (2004) G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66:1-7.
30. Moody TWHJ and Jensen RT (2003) VIP as a trophic factor in the CNS and cancer cells. Peptides 1:163-177.
31. Murthy KS, Teng B, Jin J, and Makhlouf GM (1998) G protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor. Am J Physiol 275:C1409-C1416.
32. Olah Z, Lehel C, Anderson WB, Brenneman DE, and van Agoston D (1994) Subnanomolar concentration of VIP induces the nuclear translocation of protein kinase C in neonatal rat cortical astrocytes. J Neurosci Res 39:355-363.
33. Pineau N, Lelievre V, Goursaud S, Hilairet S, Waschek JA, Janet T, and Muller JM (2001) The polypeptide PHI discriminates a GTP-insensitive form of VIP receptor in liver membranes. Neuropeptides 35:117-126.
34. Ransjo M, Lie A, Mukohyama H, Lundberg P, and Lerner UH (2000) Microisolated mouse osteoclasts express VIP-1 and PACAP receptors. Biochem Biophys Res Commun 274:400-404.
35. Rawlings SR, Piuz I, Schlegel W, Bockaert J, and Journot L (1995) Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs. Endocrinology 136:2088-2098.
36. Rosselin GMM, Besson J, and Rostene W (1982) A new neuroregulator: the vasoactive intestinal peptide or VIP. Mol Cell Endocrinol 3:243-262.
37. Vaudry D, Basille M, Yon L, Fournier A, and Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 2:269-324.
38. Zusev M and Gozes I (2004) Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 123:33-41.